Cargando…

Editorial: CAR T-Cell Therapies in Hematologic Tumors

Detalles Bibliográficos
Autores principales:	Coscia, Marta, Bruno, Benedetto, Neelapu, Sattva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596269/ https://www.ncbi.nlm.nih.gov/pubmed/33178614 http://dx.doi.org/10.3389/fonc.2020.588134

Ejemplares similares

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
por: Gatto, Lidia, et al.
Publicado: (2023)

Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
por: Nair, Ranjit, et al.
Publicado: (2020)

CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function
por: Chu, Fuliang, et al.
Publicado: (2015)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues
por: Burns, Ian, et al.
Publicado: (2022)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Editorial: COVID-19 and hematological malignancies: Volume II
por: Wilde, Lindsay, et al.
Publicado: (2022)

Editorial: Real-World evidence in onco-hematological patients
por: Vener, Claudia, et al.
Publicado: (2022)

Editorial: The management of hematologic malignancies in lower-income countries
por: Ganesan, Prasanth, et al.
Publicado: (2023)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Editorial: Characteristics and behaviors of hematopoietic stem cells and leukemia stem cells in hematologic malignancies
por: Zhang, Haojian, et al.
Publicado: (2022)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Editorial: The Emerging Role for PP2A in Hematologic Malignancies
por: Ruvolo, Peter P.
Publicado: (2016)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j7l26s0s6m2r5cicm6c9i7kdcv